Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells by Ayaki, Masahiko et al.
© 2010 Ayaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2010:4 1217–1222
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1217
OriginAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OPTH.S13708
Toxicity of antiglaucoma drugs with and without 
benzalkonium chloride to cultured human  
corneal endothelial cells
Masahiko Ayaki1
Atsuo iwasawa2
Yoichi inoue3
1Department of Ophthalmology, 
saitama national hospital, Wako, 
Japan; 2Life Particle interaction 
engineering Creation, new industry 
Creation hatchery Center, Tohoku 
University, sendai, Japan; 3Department 
of Ophthalmology, Olympia eye 
hospital, Tokyo, Japan
Correspondence: Masahiko Ayaki
Department of Ophthalmology, saitama 
national hospital, 2-1 suwa, Wako City, 
3510102 saitama, Japan
Tel +81-90-2211-8355
Fax +81-3-3705-4801
email mayaki@olive.ocn.ne.jp
Purpose: The toxicity of antiglaucoma medications to ocular surface cells has been evaluated 
extensively; however, the toxicity to corneal endothelial cells (CECs) remains elusive. Our aim is 
to evaluate the toxicity of antiglaucoma medications to CECs using an in vitro toxicity assay.
Methods: Primary cultures of human (H) CECs derived from eye bank specimens were estab-
lished. Following exposure of HCECs to test solutions for 10, 30, or 60 minutes, or 48 hours, 
we measured cell viability using a WST-1 assay. Test solutions were diluted in culture media and 
included 0.5% Timoptol®, preservative-free 0.5% timolol maleate, 1% Trusopt®, preservative-
free 1% dorzolamide, Travatan®, Travatan Z®, Xalatan®, and benzalkonium chloride (BAK). 
To assess cell viability, the value of the test culture well after treatment was expressed as a 
percentage of that of the control well. Toxicity of each solution was compared using the cell 
viability score (CVS).
Results: After exposure to 10-fold dilutions of test solutions for 48 hours, HCEC viabilities 
were 48.5% for 0.5% Timoptol, 80.9% for preservative-free 0.5% timolol maleate, 47.0% for 1% 
Trusopt, 71.7% for preservative-free 1% dorzolamide, 55.5% for Travatan, 88.5% for Travatan 
Z, and 52.5% for Xalatan. Exposure to test solutions diluted 100-fold or more resulted in HCEC 
viabilities .80%, with the exception of preservative-free 1% dorzolamide, which resulted in a 
viability of 72.0% at a dilution of 100-fold. Based on CVS, the order of cell viability was Travatan 
Z $ preservative-free timolol maleate = preservative-free dorzolamide . 0.5% Timoptol = 1% 
Trusopt . Travatan $ Xalatan. Assessment of the combined effect of drug and BAK revealed 
that latanoprost reduced the toxicity of BAK.
Conclusion: Antiglaucoma eye drops produced HCEC toxicity that appeared to depend on the 
presence of BAK. Because dilution of the antiglaucoma solutions resulted in markedly lower 
HCEC toxicity, HCEC damage due to antiglaucoma medication may occur only in rare cases. 
The CVS was useful for comparison of the toxicity of the drugs.
Keywords: cell viability score, eye drop, preservatives
Introduction
The effects of antiglaucoma drugs on the ocular surface have been investigated exten-
sively.1–4 Special attention has been paid to the cytotoxicity of benzalkonium chloride 
(BAK), included in solutions as a preservative.5–11 Glaucoma surgery using mitomycin C 
leads to a reduction in the density of corneal endothelial cells (CECs).12 By comparison, 
little is known about the toxicity of antiglaucoma eye drops to CECs.13–16 The aim of 
the present study is to evaluate the toxicity of antiglaucoma medications on human (H) 
CECs using a cell culture system. Our investigation will contribute to better long-term 
patient care especially in the cases with decreased CEC density and history of invasive 
intraocular surgeries, since glaucoma medication may continue throughout life.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Methods
The present study was approved by the Institutional Review 
Board of Showa University, Fujigaoka Rehabilitation Hospital 
(formerly the affiliation of the corresponding author).
We established primary cultures of HCECs derived from 
human eye bank specimens (SightLife, Seattle,   Washington, 
USA), as described previously.17 When sufficient cell 
numbers for bioassay were obtained, cells were harvested. 
A 100-µL aliquot of the culture, containing approximately 
2 × 104 cells, was replated, and cells were cultured for 
2 days before exposure to test solutions. Table 1 shows 
the antiglaucoma solutions evaluated in the present study. 
Preservative-free 0.5% timolol maleate and preservative-
free 1% dorzolamide were prepared for the present inves-
tigation only. Test solutions were used undiluted or diluted 
2-, 10-, 100-, 1,000-, or 10,000-fold. 0.01% and 0.005% 
BAK (Wako Pure Chemical Industries, Osaka, Japan) were 
also tested.
After exposure to the test solutions for 10, 30, or 60 minutes, 
or 48 hours, cell viability was assayed using 4-[3-(4-iodophenyl)-
2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate 
(WST-1; Dojindo Laboratories, Kumamoto, Japan). 
The WST-1 assay is a quantitative colorimetric assay that 
measures mitochondrial activity as an index of cell viability 
and proliferation. It only detects living cells, and the signal 
generated is directly proportional to the number of live cells. 
At the completion of the assays, absorbance was read on a 
spectrophotometer (Benchmark microplate reader; Bio-Rad, 
Hercules, California, USA). Control wells were incubated 
with growth media without test solution. To calculate cell 
viability, the value of the signal from the treated culture 
well was expressed as a percentage of that of the control 
well. Experiments were repeated between 8 and 16 times, 
and results were expressed as the mean ± standard devia-
tion. The first established cell line was used for assays after 
48 hours’ exposure, and the second one was for 10, 30, and 
60 minutes’ exposure. Each of these was cultivated from 4 
corneas. Statistical analysis with Student’s t test was per-
formed using Microsoft Excel (Tokyo, Japan).
We expressed the results of the viability of cells after 10, 
30, or 60 minutes’ exposure as a cell viability score (CVS) 
to enable easy comparison of the effects of different drugs. 
This concept is similar to the minimum inhibitory concen-
tration (MIC50) of a drug required to inhibit the growth of 
50% of organisms. CVSs are calculated as follows: (1) The 
toxicological tests are performed in undiluted, 2-fold or 
10-fold diluted solutions for 10, 30, or 60 minutes’ expo-
sure. (2) The cell viability value in any solution is found to 
be ,80% in any conditions, and confirmed cell viability 
is  $80% after adequate dilutions for every solution. (3) The 
CVS50 is determined for each solution in each condition as 
the number of experiments for a viability value $50%.The 
CVS40/80 is calculated as follows: CVS40/80 = (number 
of experiments for a viability value .80%) − (number of 
Table 1 Antiglaucoma eye drops evaluated in the present study
Active component Trade name  
and manufacturer
Preservative CVS50a CVS40/80a
Timolol maleate (0.5%) 0.5% Timoptol (Banyu  
Pharmaceutical, Tokyo, Japan)
0.005% BAK 5 2 
(4–2)
Preservative-free timolol maleate (0.5%) no trade name and prepared for  
investigational use only. Provided  
by Merck and Co, Whitehouse  
station, nJ, UsA
none 9 7 
(7–0)
Dorzolamide (1%) 1% Trusopt (Banyu  
Pharmaceutical)
0.005% BAK 6 2 
(5–3)
Preservative-free dorzolamide (1%) no trade name and prepared for  
investigational use only. Provided  
by Merck and Co
none 9 6 
(6–0)
Travoprost (0.004%) Travatan (Alcon Laboratories,  
Fort Worth, TX, UsA)
0.015% BAK  4 0 
(3–3)
Travoprost (0.004%) Travatan Z (Alcon Laboratories) sofZia system 9 9 
(9–0)
Latanoprost (0.005%) Xalatan (Pfizer, New York,  
nY, UsA)
0.02% BAK 3 −4 
(2–6)
Note: aThe CVs was calculated after 10, 30, or 60 minutes’ exposure of each drug as follows: CVs40/80 = (number of viability values .80%) − (number of viability values ,40%);   
CVs50 = number of viability value $50%.
Abbreviations: CVs, cell viability score; BAK, benzalkonium chloride; sofZia, an ionic buffering preservative system containing borate, sorbitol, propylene glycol, and zinc.11,34Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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experiments for viability value ,40%). (4) A total of CVS 
for multiple (2 or more concentrations or exposure times) 
conditions is relevant for general evaluation. Although some 
CVS for a single condition seems suitable to determine the 
order of toxicity such as 2-fold dilution after 30 or 60 min-
utes’ exposure (eg, Figure 1), note especially that these 
results are not always consistent with the result from a total 
of CVS or the general trend observed in graphic expres-
sion. (5) As for determination of the order of toxicity of the 
tested solutions, the significant difference in actual scores 
should be .20% of a total number of experiments under the 
condition for CVS. Consequently, the order of toxicity is 
expressed by “,” and “.” for the difference $20%, “#”, 
“$”, and “ = ” for the difference from 0% to 20%. In the 
present study, a total of 9 experiments were conducted, 
and we defined significant difference as 2 or more scores. 
When the orders determined by CVS50 and CVS40/80 
are conflicting, a final decision is made by uniting both 
results or by considering CVS for individual concentration 
or exposure time to explore the trend. The CVS system is 
subject to change according to tested solutions, cell lines, 
toxicological methods, and other factors. We used CVS in 
prior studies18–20 and found it useful. Comparisons of cell 
viability were also made between a drug with BAK and the 
corresponding drug without BAK.
Results
The cell viabilities of HCECs exposed to test solutions 
are shown in Figure 1. HCEC viabilities after exposure to 
10-fold dilutions of test solutions for 48 hours were, eg, 
48.5% for 0.5% Timoptol (Banyu Pharmaceutical, Tokyo, 
Japan), 80.9% for preservative-free 0.5% timolol maleate, 
47.0% for 1% Trusopt (Banyu Pharmaceutical), 71.7% for 
preservative-free 1% dorzolamide, 55.5% for Travatan 
(Alcon Laboratories, Fort Worth, Texas, USA), 88.5% for 
Travatan Z (Alcon Laboratories), and 52.5% for Xalatan 
(Pfizer, New York, NY, USA). Cell viability .80% was 
seen after incubation with 100-fold dilutions of test solu-
tions, with the exception of preservative-free 1% dorzo-
lamide, which resulted in 72.0% viability. We confirmed 
cell viability exceeded 80% in 1,000-fold or 10,000-fold 
dilution for every solution including 48 hours’ exposure. 
Using CVS as an indicator of cytotoxicity, the order of 
cell viability after short exposure (10, 30, or 60 minutes) 
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Figure 1 Viability of cultured human corneal endothelial cells after exposure to antiglaucoma eye drops for 10, 30, or 60 minutes, or 48 hours. exposure to drugs containing 
the preservative benzalkonium chloride led to markedly lower cell viability, especially at higher concentrations and following longer exposure. Data are expressed as the 
mean ± standard deviation. Drugs without benzalkonium chloride are represented by open symbols and solid lines.
Note: *P , 0.01 (student’s t test) or ns for comparisons of *1,ns1Timoptol vs preservative-free timolol maleate; *2,ns2Trusopt vs preservative-free dorzolamide, and 
*3,ns3Travatan vs Travatan Z in each concentration and exposure time.
Abbreviation: ns, nonsignificant.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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to the solutions was Travatan Z $ preservative-free 
timolol maleate = preservative-free dorzolamide .0.5% 
  Timoptol = 1% Trusopt .   Travatan $ Xalatan (Table 1). As 
for the cell viability after 48 hours’ exposure, the difference 
between the solutions with BAK and those without BAK was 
clear in 10-fold dilution (Figure 1, far right panel). However, 
cell viabilities were .70% in all of the 100-fold diluted 
solutions and the difference was not clear. We assessed the 
effect of antiglaucoma medications with and without BAK 
  statistically, which revealed that cell viability in the presence 
of BAK was markedly lower, especially with higher concen-
trations and following longer exposure (Figure 1).
Cell viabilities following treatment with BAK alone or 
antiglaucoma solutions containing comparable BAK concen-
trations are shown in Figure 2. Cell viabilities were lower 
for 0.5% Timoptol and 1% Trusopt than for 0.005% BAK 
(P , 0.01). In comparison, higher cell viabilities were seen 
with Xalatan (used at a 2-fold dilution, containing 0.01% 
BAK) and Travatan (used at a 2-fold dilution, containing 
0.0075% BAK) than for 0.01% BAK alone (P , 0.01, 
P , 0.01).
Discussion
BAK is toxic for CECs, and several clinical cases have been 
reported21–25 for accidental introduction of BAK into the 
anterior chamber and for instillation of BAK-containing 
solutions to the eyes with or without disrupted ocular surface 
barrier function. The antiglaucoma medications containing 
BAK were significantly more toxic to HCECs than   solutions 
without BAK. Our results are similar to those of other studies 
using ocular surface cells.1–11 Considering the actual concen-
tration of drugs (1,000- to 10,000-fold dilution in aqueous 
humor)26,27 to which HCECs are exposed after topical admin-
istration and the fact that toxicity decreased markedly after 
dilution in the present study, HCEC loss due to antiglaucoma 
medication may only occur in rare cases.
Timolol maleate was the standard antiglaucoma medica-
tion until prostaglandin analogs were introduced. Previous 
studies of its side effects on ocular surface cells demonstrated 
that timolol maleate itself has acceptable toxicity and that 
BAK and other ingredients in commercial timolol maleate 
eye drops, as well as interaction of each component, play a 
major role in their toxicity,9,28,29 which was confirmed by the 
present results for HCECs. Treatment with Trusopt has been 
reported to result in corneal edema; however, this side effect 
only appeared in patients with compromised corneas and 
a previous history of corneal pathology.30 Previous studies 
and the results of the present study suggest that Trusopt and 
preservative-free dorzolamide are not significantly toxic to 
CECs under usual ocular conditions.15,29,31–33
Travatan Z was less toxic to HCECs than Travatan contain-
ing the preservative BAK. Travatan Z uses SofZia, a unique 
0
20
40
60
80
100
120
Travatan Z
Preservative-free 0.5% timolol
Preservative-free 1% dorzolamide
0.005% BAK
0.5% Timoptol
1% Trusopt
Travatan (2-fold diluted)
Xalatan (2-fold diluted)
0.01% BAK
Xalatan
Travatan
E
n
d
o
t
h
e
l
i
a
l
 
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)
***
**
Figure 2 effect of antiglaucoma eye drops and BAK on the viability of cultured human corneal endothelial cells after 30 minutes’ exposure. BAK was used at concentrations of 
0.01% and 0.005%. note that cell viabilities were lower for 0.5% Timoptol and 1% Trusopt than for 0.005% BAK. in comparison, higher cell viabilities were seen with Xalatan 
(used at a 2-fold dilution, containing 0.01% BAK) and Travatan (used at a 2-fold dilution, containing 0.0075% BAK) than for 0.01% BAK alone.
Note: Data are expressed as the mean ± standard deviation. *P , 0.01 (student’s t test). 
Abbreviation: BAK, benzalkonium chloride.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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ionic buffering preservative system containing borate, sorbitol, 
propylene glycol, and zinc.11,34 Our assessment of the combined 
effect of antiglaucoma compounds and BAK revealed that 
cell viability for timolol maleate (Timoptol) and dorzolamide 
(Trusopt) eye drops with BAK was much lower than that 
for comparable concentration of BAK, whereas latanoprost 
(Xalatan), and probably travoprost (Travatan) did not exhibit 
lower cell viability to HCECs than BAK alone (Figure 2). 
Our results on HCECs could not confirm previous findings 
for a protective effect of latanoprost and travoprost against the 
toxicity of BAK on conjunctival cells.35 Owing to the limited 
number of cultured HCECs available, we were not able to 
examine the effect of BAK at exactly the same concentration 
as that contained in Travatan. Further investigations with 
additional methodologies are necessary to properly evaluate 
the cytotoxicity of antiglaucoma medications.
The comparison of drug toxicity with graphic expression 
of a series of measurements is often difficult. Using CVS 
reference values of 40%, 50%, or 80% enables numerical 
expression, leading to a better comparison of solution toxicity. 
The reference point of 50% for CVS50 is a direct application 
of MIC50. 80% for CVS40/80 is a border between nontoxic 
and toxic, and 40% is a border between toxic and very toxic 
according to our experience of assay with numerous cells 
and reagents. The CVS was a useful evaluation method for 
comparison of cell viability values obtained from multiple 
series of toxicity assays.
The concentration of tested solutions was very high 
compared with the actual concentration in aqueous humor 
after instillation, because the present study is a so-called 
accelerated experiment. We were unable to construct a culture 
system to observe toxicity over a long time in the solution 
of very low concentration. Consequently, we set up experi-
ments in solutions of high concentrations to detect significant 
toxicity after reasonable incubation. The major difficulties 
in eye drop toxicity studies include setting exposure time 
and concentration, since both tear and aqueous humor are 
continuously exchanged in a living eye. This is the reason 
why our setting covers many exposure times and dilutions to 
explore toxicity in various environments. The short exposures 
may simulate accidental introduction of the drug to endothe-
lial cells, and 48 hours’ exposure may simulate long-term or 
repeated instillations.
Conclusion
Antiglaucoma eye drops produced HCEC toxicity that 
appeared to depend on the presence of BAK. The CVS 
was useful in comparing the cytotoxicity of different 
drugs, and the order of cell viability in tested solutions 
determined by CVS was Travatan Z $ preservative-free 
timolol maleate = preservative-free dorzolamide . 0.5% 
Timoptol = 1% Trusopt . Travatan $ Xalatan. Because 
dilution of the antiglaucoma solutions resulted in markedly 
lower HCEC toxicity, HCEC damage due to antiglaucoma 
medication may occur only in rare cases.
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